Legal Representation
Attorney
Larry L. Coats
USPTO Deadlines
Next Deadline
2058 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250812)
Due Date
August 12, 2031
Grace Period Ends
February 12, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
38 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 12, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Aug 12, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 23, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jul 23, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jul 18, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Apr 3, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jul 16, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Apr 3, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 8, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 13, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 13, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 24, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 11, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 10, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 10, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 10, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 5, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 5, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 5, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 3, 2024 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Jun 9, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 15, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 14, 2024 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| May 1, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 1, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 1, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 1, 2024 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 1, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Apr 25, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 25, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 25, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 29, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 29, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 29, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 29, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 15, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| May 31, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 5, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Business management and administration of pharmacy reimbursement programs; Managing and administering the distribution of prescription pharmaceutical samples to physicians and patients for pharmaceutical manufacturers; Business management and administration of patient co-pay reimbursement programs on behalf of pharmaceutical manufacturers; Business management and administration of financial assistance programs that provide patients with access to affordable medicine, namely business management and administration of enrollment and reimbursement programs for the purchase of medication and generally facilitating access to medications; Business management and administration of patient support programs for pharmaceutical manufacturers; Business management and administration of patient engagement programs for pharmaceutical manufacturers; Business management and administration of formulary, patient, and payer policy information for pharmaceutical, medical device, and diagnostic manufacturers; Business management and administration of educational engagements for Health Care Providers, namely, business management and administration of efforts to educate healthcare providers on medications, disease status and standard of care; Management of the distribution of clinical trial medication and supplies on behalf of pharmaceutical manufacturers; Providing business marketing information, namely, tracking pharmaceutical promotional programs for pharmaceutical manufacturers and evaluating and determining their effectiveness; Data management services in the field of pharmaceutical patient safety, namely, collecting adverse product events data, storing the data, and reporting collected adverse product events data; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, promoting awareness of diseases, pharmaceutical brands, and treatment affordable options; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, marketing services in the nature of promotion of pharmaceutical manufacturers and disease treatment options via social media; Business information services, namely, tracking payer coverage policies and related documentation and providing life sciences clients access to such in order to enhance their market access strategies and patient support programs; Life science business strategy consulting services for assisting clients with commercial assessments, corporate and portfolio strategy, new product planning and commercialization support, and pricing and market access insights; Business assistance services, namely, enrolling patients of pharmaceutical manufacturers into support programs that enable patients to view, track, and manage the support program wherein the patient support program provides pharmaceutical consumer product information, payer coverage status updates, and providing business information regarding access to enrollment and reimbursement programs for the purchase of medications; Providing business information and news to the pharmaceutical and life sciences industries on legislative and regulatory developments as it impacts and relates to the pharmaceutical and life sciences industries within the copay or patient affordability space
First Use Anywhere:
Sep 20, 2023
First Use in Commerce:
Sep 20, 2023
Class 036
Payment services, namely, reimbursement payment processing in the field of pharmaceutical financial assistance programs and loyalty program payment processing services provided on behalf of pharmaceutical manufacturers for the purpose of delivering benefits to patients enrolled in pharmaceutical manufacturer-sponsored financial assistance programs; Pharmacy benefit manager (PBM) accumulator mitigation services and detecting claim activity indicative of a pharmacy benefit manager attempting to abuse the use of co-pay cards by not applying amounts paid by clients towards the patient's deductible or annual out-of-pocket expense; Anti-kickback and risk mitigation services for the pharmaceutical industry, namely, antikickback compliance services for assuring that patients who have full or partial federally funded drug coverage are excluded from utilizing co-pay cards
First Use Anywhere:
Sep 20, 2023
First Use in Commerce:
Sep 20, 2023
Class 041
Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, providing podcasts, seminars, workshops, and virtual and in-person presentations for educational purposes in the field of diseases, pharmaceutical brands, and affordable healthcare options
First Use Anywhere:
Sep 20, 2023
First Use in Commerce:
Sep 20, 2023
Class 042
Quality assurance and quality control patient claim services for monitoring paid claims to patients from insurance or pharmaceutical entities to insure that specific business rules are being correctly applied to patient claims; Pharmacovigilance services for others, namely, scientific research and analysis pertaining to adverse events and product quality complaints regarding pharmaceutical products, assessment of risks presented by certain pharmaceutical products or combinations thereof, and product safety testing and consultation related thereto in the field of pharmaceuticals; Pharmacovigilance services for others, namely, monitoring the quality of efficacy of pharmaceutical preparations; Providing online non-downloadable software for patient support services, namely, for enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services including injection and product educational training, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications
First Use Anywhere:
Sep 20, 2023
First Use in Commerce:
Sep 20, 2023
Class 045
Pharmacy benefit fraud monitoring, namely, investigation services related to pharmacy benefit insurance claims
First Use Anywhere:
Sep 20, 2023
First Use in Commerce:
Sep 20, 2023
Classification
International Classes
035
036
041
042
045